LQDA - NASDAQ

Liquidia Corporation

LQDA·NASDAQ

$55.69

+1.5%

HealthcareBiotechnology

Liquidia Corporation, a biopharmaceutical company, develops, manufactures, and commercializes various products for unmet patient needs in the United States. Its product candidates include YUTREPIA, an inhaled dry powder formulation of treprostinil for the treatment of pulmonary arterial hypertension. It also distributes generic treprostinil injection in the United States. Liquidia Corporation was founded in 2004 and is headquartered in Morrisville, North Carolina.

Statements Value Model

At a Glance

Live Snapshot

Market Cap$4.95B

EPS-0.8000

P/E Ratio-69.61

Earnings Date08/11/2026

327.93M

Assets

42%

3Y+154.0%

5Y+229.0%

10Y+3764.0%

283.19M

Total Liabilities

85%

3Y+630.0%

5Y+896.0%

10Y+959.0%

44.75M

Total Equity

-42%

3Y-51.0%

5Y-37.0%

10Y-345.0%

Liquidia Corporation Funding & Solvency Profile

LQDA · NASDAQ

Current Assets

Cash & Cash Equivalents190.68M

Net Receivables54.09M

Inventory0.00

Other Current Assets-54.09M

Total Current Assets191 M

Non-Current Assets

Property, Plant & Equipment0.00

Goodwill & Intangible Assets6.86M

Long-Term Investments3.50M

Other Non-Current Assets126.89M

Total Non-Current Assets130 M

Total Assets

327.93M

Financial Health Analysis

Current Ratio

1.40x

Acceptable liquidity, but monitor closely. Current assets just barely cover current liabilities.

Debt-to-Equity Ratio

6.33x

High financial leverage. Heavy reliance on debt may indicate increased financial risk and potential solvency concerns.

Working Capital

55 M

Positive working capital, but relatively tight. The company should monitor cash flow carefully.

Asset Composition

58% Current

Balanced asset mix between current and non-current assets, typical of many stable businesses.

Liquidia Corporation Balance Sheet

LQDA • NASDAQ

Liquidia Corporation Balance Sheet	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020	Dec 2019	Dec 2018	Dec 2017	Dec 2016
ASSETS
CURRENT ASSETS
Cash and Cash Equivalents	190.7M	176.5M	83.7M	93.3M	57.5M	65.3M	55.8M	39.5M	3.4M	1.4M
Cash & Short-Term Investments	190.7M	176.5M	83.7M	93.3M	57.5M	65.3M	55.8M	39.5M	3.4M	1.4M
Net Receivables	54.1M	2.7M	4.1M	5M	3M	0.0	0.0	272.6K	1.6M	1.2M
Accounts Receivables	54.1M	2.7M	4.1M	5M	3M	0.0	0.0	272.6K	1.6M	1.1M
Other Receivables	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	89.3K
Inventory	0.0	241K	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Prepaids	0.0	0.0	0.0	0.0	792.4K	752.4K	590.3K	219.1K	123.7K	468.7K
Other Current Assets	-54.1M	5.7M	2.2M	1.5M	-381.0	0.0	0.0	0.0	0.0	0.0
Total Current Assets	190.7M	185.1M	89.9M	99.8M	61.3M	66.1M	56.4M	40M	5.5M	3.1M
NON-CURRENT ASSETS
Property, Plant, and Equipment (Net)	0.0	12.5M	6.2M	6.3M	7.4M	9.5M	12.1M	8.1M	8.2M	4.3M
Goodwill	3.9M	3.9M	3.9M	3.9M	3.9M	3.9M	0.0	0.0	0.0	0.0
Intangible Assets	3M	3.2M	3.4M	3.7M	4.4M	5.5M	0.0	0.0	0.0	0.0
Goodwill & Intangible Assets	6.9M	7.1M	7.3M	7.6M	8.3M	9.4M	0.0	0.0	0.0	0.0
Long-Term Investments	3.5M	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Other Non-Current Assets	126.9M	25.7M	14.9M	15.5M	16.7M	14.6M	378K	1.3M	1.1M	992.7K
Total Non-Current Assets	137.3M	45.2M	28.4M	29.4M	32.5M	33.5M	12.5M	9.4M	9.4M	5.3M
Total Assets	327.9M	230.3M	118.3M	129.2M	93.7M	99.5M	68.8M	49.4M	14.8M	8.5M
LIABILITIES
CURRENT LIABILITIES
Total Payables	3.7M	4.7M	1.4M	2.2M	1.1M	3.7M	3.5M	3.2M	4.4M	2.4M
Accounts Payable	3.7M	4.7M	1.4M	2.2M	1.1M	3.7M	3.5M	3.2M	4.4M	2.4M
Accrued Expenses	0.0	0.0	4.9M	2.7M	2M	1.4M	4.7M	4M	4.2M	2M
Short Term Debt	58.9M	18M	2.6M	0.0	0.0	0.0	5.6M	316.9K	15.6M	2.9M
Capital Lease Obligations (Current)	0.0	417K	1.1M	1.1M	1.1M	1.6M	1.8M	452.7K	469.8K	324.5K
Deferred Revenue	0.0	0.0	0.0	0.0	0.0	0.0	0.0	8.1B	3.6M	3.3M
Other Current Liabilities	73.2M	18.7M	8.5M	2.9M	3.2M	5M	1.3M	268.6K	2.2M	1.2M
Total Current Liabilities	135.8M	41.8M	18.6M	8.8M	7.3M	11.7M	16.9M	8.2M	30.5M	12.1M
NON-CURRENT LIABILITIES
Long Term Debt	132.9M	97.4M	43.4M	19.9M	10.4M	10.3M	10.3M	11.6M	5.6M	5.2M
Deferred Revenue (Non-Current)	0.0	0.0	0.0	0.0	0.0	0.0	0.0	8.1M	5.5M	8.7M
Deferred Tax Liabilities (Non-Current)	3.6M	0.0	0.0	0.0	0.0	0.0	0.0	-376.1K	-510.6K	-243.4K
Other Non-Current Liabilities	4.7M	7.3M	6.7M	6.6M	6.1M	1.2M	0.0	2.4M	6.4M	456.9K
Total Non-Current Liabilities	147.4M	111.3M	52.5M	30M	21.1M	16.7M	17M	22.5M	18M	14.6M
Capital Lease Obligations	6.1M	7M	3.5M	4.6M	5.7M	6.8M	8.5M	828.8K	980.4K	567.9K
Total Liabilities	283.2M	153M	71M	38.8M	28.5M	28.4M	33.9M	30.7M	48.5M	26.7M
SHAREHOLDERS' EQUITY
Preferred Stock	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	43K	43K
Common Stock	87K	85K	69K	64K	52K	43.3K	28.2K	15.5K	570.0	554.0
Additional Paid-In Capital	671M	636.7M	476.3M	441M	374.8M	346M	250.2M	185.7M	79.7M	66M
Retained Earnings	-626.3M	-559.5M	-429.1M	-350.6M	-309.6M	-275M	-215.2M	-167.1M	-113.4M	-84.3M
Accumulated Other Comprehensive Income/Loss	0.0	0.0	0.0	0.0	0.0	0.0	0.0	-9.3M	-7.8M	-6.9M
Other Total Stockholders' Equity	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	6.9M
Total Stockholders' Equity	44.7M	77.3M	47.3M	90.4M	65.3M	71.1M	34.9M	18.7M	-33.7M	-18.2M
Total Equity	44.7M	77.3M	47.3M	90.4M	65.3M	71.1M	34.9M	18.7M	-33.7M	-18.2M
SUMMARY
Total Liabilities & Equity	327.9M	230.3M	118.3M	129.2M	93.7M	99.5M	68.8M	49.4M	14.8M	8.5M
Total Investments	3.5M	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Total Debt	197.9M	122.4M	49.5M	24.5M	16.1M	17.1M	24.4M	12.8M	22.1M	8.7M
Net Debt	7.2M	-54.1M	-34.1M	-68.8M	-41.4M	-48.2M	-31.4M	-26.8M	18.7M	7.2M
Shares Outstanding	85,451,851	85,451,851	85,451,851	85,451,851	85,451,851	85,451,851	85,451,851	85,451,851	85,451,851	85,451,851

SEC Filings

LQDA - Filing history and reports

Filing Type	Filing Date	Period Ending	Fiscal Year	Actions
10-Q 10-Q 2026 Q1 Q1	May 11, 2026	March 31, 2026	2026	View Filing
8-K 8-K 2026 N/A	May 11, 2026	May 11, 2026	2026	View Filing
DEF 14A DEF 14A 2026 N/A	April 24, 2026	June 16, 2026	2026	View Filing
10-K 10-K 2025 FY FY	March 05, 2026	December 31, 2025	2025	View Filing
8-K 8-K 2026 N/A	March 05, 2026	March 05, 2026	2026	View Filing
8-K 8-K 2026 N/A	January 09, 2026	January 09, 2026	2026	View Filing
8-K 8-K 2025 N/A	November 03, 2025	November 03, 2025	2025	View Filing
10-Q 10-Q 2025 Q3 Q3	November 03, 2025	September 30, 2025	2025	View Filing
8-K 8-K 2025 N/A	October 30, 2025	October 27, 2025	2025	View Filing
10-Q 10-Q 2025 Q2 Q2	August 12, 2025	June 30, 2025	2025	View Filing

Showing 1 to 10 of 147 filings

Related Guides

Blog Categories

Continue your LQDA research with focused valuation guides.

Fundamentals

Decode statement quality and operating durability.

Accounting

Interpret line items with cleaner analytical framing.

Forecasting

Translate historical performance into forward scenarios.

Reference

Use practical frameworks for statement-led valuation.

Research Paths

Pick your next lens

Snapshot

Start with context, operating signals, and key market metrics.

Value Model

Stress test fair value across bear, base, and bull assumptions.

Statements

Validate revenue quality, margins, and balance sheet durability.

Earnings Call

Read management commentary and compare it with reported outcomes.

Dividends

Check payout sustainability and long-term distribution behavior.

Analyst Expectations

Review consensus spread and where estimate risk is concentrated.